What are the indications, dosing schedule, and contraindications for aripiprazole long‑acting injection (Abilify LA)?

Abilify Maintena (Aripiprazole Long-Acting Injectable)

Abilify Maintena is FDA-approved for treatment of schizophrenia and maintenance monotherapy of bipolar I disorder in adults, administered as 400 mg intramuscular injection monthly (or 300 mg for dose reduction), with the critical requirement that patients must first establish tolerability with oral aripiprazole before initiating the long-acting formulation 1.

Indications

Abilify Maintena is indicated for:

• Treatment of schizophrenia in adults
• Maintenance monotherapy treatment of bipolar I disorder in adults 1

The use of long-acting injectable antipsychotics should be considered for any patient requiring long-term treatment, particularly those with irregular medication adherence, given the well-established relationship between non-adherence and relapse risk 2. While LAIs remain underutilized despite frequent non-adherence with oral medications 2, they represent a valuable tool for preventing relapse and rehospitalization.

Dosing Schedule

Pre-Treatment Requirements

Before initiating Abilify Maintena, you must establish tolerability with oral aripiprazole in patients naïve to the medication 1. This is non-negotiable and prevents adverse reactions in patients who cannot tolerate aripiprazole.

Standard Dosing

• Recommended dose: 400 mg administered monthly as a single intramuscular injection
• Can be reduced to 300 mg monthly in patients experiencing adverse reactions 1
• Administration site: Deltoid or gluteal muscle by healthcare professional only 1

Initiation Protocols

There are two FDA-approved initiation methods 1:

1-Day Initiation (Two-Injection Start):

• Administer two separate 400 mg intramuscular injections of Abilify Maintena on day 1
• Give single oral dose of aripiprazole 20 mg on day 1
• Recent evidence suggests this approach maintains therapeutic levels within the therapeutic window while avoiding peaks above it, potentially increasing safety 3

14-Day Initiation (One-Injection Start):

• Administer first 400 mg injection
• Continue 14 consecutive days of concurrent oral aripiprazole (10-20 mg daily) OR continue current oral antipsychotic for 14 days 1
• Note: This traditional approach may expose patients to serum levels above the therapeutic window, potentially increasing toxicity risk 3

Special Populations & Drug Interactions

CYP2D6 Poor Metabolizers:

• Reduce dose to 300 mg monthly as starting and maintenance dose 1

Concomitant CYP2D6 or CYP3A4 Inhibitors (>14 days):

• Dose modifications required—consult full prescribing information 1

CYP3A4 Inducers:

• Avoid concomitant use for >14 days (e.g., carbamazepine can significantly reduce aripiprazole levels, leading to symptom breakthrough) 4

Missed Dose Management

Dosage adjustments are required for missed doses 1. The medication allows a ±7 day dosing window. If this window is exceeded, catch-up protocols may involve administering the next dose immediately, using supplemental oral aripiprazole for 14 days as a bridge, or restarting initiation loading regimens entirely 4.

Extended Formulation

A 2-month formulation (Ari2M) is now available as 960 mg or 720 mg doses administered every 2 months in the gluteal muscle only, with a ±2 week dosing window. Reinitiation is only necessary if ≥14 weeks have passed since the prior injection 5.

Contraindications

Absolute Contraindication:

• Known hypersensitivity to aripiprazole 1

Critical Warnings & Precautions

Black Box Warning

Increased mortality in elderly patients with dementia-related psychosis—Abilify Maintena is NOT approved for this population 1.

Major Safety Concerns

Cerebrovascular adverse reactions: Increased incidence of stroke and TIA (including fatalities) in elderly patients with dementia-related psychosis 1

Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring 1

Tardive Dyskinesia: Discontinue if clinically appropriate 1

Metabolic changes (hyperglycemia, dyslipidemia, weight gain):

• Monitor BMI, waist circumference, blood pressure weekly for 6 weeks after initiation
• Check fasting glucose at baseline and 4 weeks post-initiation
• Repeat all metabolic parameters at 3 months, then annually 6
• Most common adverse reactions (≥5% and twice placebo): increased weight, akathisia, injection site pain, sedation 1

Pathological gambling and compulsive behaviors: Consider dose reduction or discontinuation 1

Orthostatic hypotension: Use caution in cardiovascular/cerebrovascular disease 1

Leukopenia/Neutropenia/Agranulocytosis: Monitor complete blood counts in patients with history of low WBC/ANC 1

Seizures: Use cautiously in patients with seizure history 1

Cognitive and motor impairment: Caution with machinery operation 1

Managing Adverse Effects

For akathisia: Reduce LAI dose or use short-term adjunctive treatments like vitamin B6 or mirtazapine until dose adjustments reach steady state 4. Alternatively, consider switching to a lower-risk profile agent.

For drug-induced Parkinsonism: Reduce the LAI dose or switch to agents with lower extrapyramidal side-effect profiles 4.

Clinical Context

Long-acting injectables are particularly valuable for patients with schizophrenia or bipolar I disorder who have demonstrated non-adherence patterns, as even one or two relapses early in illness can significantly diminish academic, vocational, and social opportunities 2. The pattern of hospitalization, non-adherence, and rehospitalization often repeats multiple times before LAI is considered, representing a missed opportunity for relapse prevention 2.